Novartis Lost $32 Billion in a Day — Two Failed Drug Bets Exposed One Pipeline Risk
Del-desiran missed its Phase III primary endpoint days after pelacarsen disappointed, forcing investors to reassess whether an acquisition-built pipeline can offset approaching patent losses.
9 Sep 2026, 8:26 AM IST